Erudio Healtherudio.com
Indication
Gastric cancer trials: what clinicians said in public
No HCP commentary report on a trial in gastric cancer yet. Erudio has found public clinician commentary on 3 clinical trials in gastric cancer: DESTINY-Gastric02, HERIZON-GEA-01 and KEYNOTE-811. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| KEYNOTE-811 NCT03615326 · Merck Sharp & Dohme LLC DeepView → | first-line HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| HERIZON-GEA-01 NCT05152147 · Jazz Pharmaceuticals DeepView → | HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma | Phase 3 | Deep | View | |||
| DESTINY-Gastric02 NCT04014075 · Daiichi Sankyo DeepView → | HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma | Phase 2 | Deep | View | |||